Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03375047 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
A Phase 1 study of Cystic Fibrosis, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 16
- Study locations
NCT03375047 is a Phase 1 study of Cystic Fibrosis that has completed, run by Sanofi. The registered enrollment target is 42 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (77% lower). The trial reports 16 study locations across 14 states.
The verdict
NCT03375047, a Phase 1 study of Cystic Fibrosis, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 16
- Study locations
Study Summary
This Phase 1/2, first-in-human study evaluated the safety and tolerability of single and multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of adult subjects with cystic fibrosis (CF).
Conditions Studied
Interventions
- DRUG Normal saline
- DRUG MRT5005
Study Locations (16)
Ohio
- University of Cincinnati - Cincinnati
- University Hospitals - Cleveland
- Nationwide Children's Hospital - Columbus
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- National Jewish Health - Denver
Florida
- University of Florida - Gainesville
Illinois
- Northwestern University - Chicago
Indiana
- University of Indiana - Indianapolis
Maine
- Maine Medical Center - Portland
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-05-10 |
| Est. Completion | 2022-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03375047
The ClinicalTrials.gov registry entry for NCT03375047 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (77% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.
NCT03375047 reports 16 study locations spanning 14 distinct geographic areas - top geographies include Ohio, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT03375047 about?
NCT03375047 is a clinical study titled "Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis". This Phase 1/2, first-in-human study evaluated the safety and tolerability of single and multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of adult subjects with cystic fibrosis (CF).
What is the current status of trial NCT03375047?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2018-05-10. Estimated completion is 2022-03-15.
What conditions does trial NCT03375047 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT03375047?
The interventions under investigation include: Normal saline (DRUG), MRT5005 (DRUG).
Who is sponsoring clinical trial NCT03375047?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03375047 being conducted?
This trial has 16 study locations across Alabama, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.